We are excited to announce the close of Lygos’ $15.5MM Series B round of financing. Led by IA Ventures and First Round Capital, these funds will be used to accelerate commercialization of our pipelined products and expand our technology platform. Having successfully developed a bio-based route to malonates, we now look forward to bringing new aspartic, glycolic, and lactic acid technologies to market, among others.
Read more: